Skip to content
MedsAcross

Medicine

Cladribine 10 mg tablet

Cladribine · Oral
Available on requestPrescription onlyUS FDAGeneric name

Cladribine 10 mg tablet is a generic prescription medicine for oral use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), excursions…

Key facts

Active ingredient (INN)
Cladribine
Brand
Sold under the generic name
Strength
10 mg
Dosage form
Tablet
Route
Oral
Packs
10 tablets, 4 tablets, 5 tablets and 18 more
Manufacturers
ApotexGenvionSandoz
Origin register
US FDA, United States
Storage
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store in original package in order to protect from moisture.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01BB04 Cladribine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
25 November 2025
Identifiers
RxCUI 2122634, 2122635, 2122647 +5DailyMed set ID e0b363cb-db83-44d6-89d0-1f7176be7459, f1d650a5-4205-720b-f39b-4213277b6612, 407c52d5-6498-7da5-da35-acc9ca73ced3NDC 0781-8201, 62049-286, 60505-4791Application ANDA215547, ANDA218425

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
10 tablet in 1 carton60505-4791-1Apotex25 November 2025
4 tablet in 1 carton60505-4791-4Apotex25 November 2025
5 tablet in 1 carton60505-4791-5Apotex25 November 2025
6 tablet in 1 carton60505-4791-6Apotex25 November 2025
7 tablet in 1 carton60505-4791-7Apotex25 November 2025
8 tablet in 1 carton60505-4791-8Apotex25 November 2025
9 tablet in 1 carton60505-4791-9Apotex25 November 2025
4 tablet in 1 carton62049-286-04Genvion25 November 2025
5 tablet in 1 carton62049-286-05Genvion25 November 2025
6 tablet in 1 carton62049-286-06Genvion25 November 2025
7 tablet in 1 carton62049-286-07Genvion25 November 2025
8 tablet in 1 carton62049-286-08Genvion25 November 2025
9 tablet in 1 carton62049-286-09Genvion25 November 2025
10 tablet in 1 carton62049-286-10Genvion25 November 2025
9 tablet in 1 carton0781-8201-37Sandoz29 April 2026
5 tablet in 1 carton0781-8201-51Sandoz29 April 2026
6 tablet in 1 carton0781-8201-68Sandoz29 April 2026
7 tablet in 1 carton0781-8201-71Sandoz29 April 2026
10 tablet in 1 carton0781-8201-80Sandoz29 April 2026
8 tablet in 1 carton0781-8201-85Sandoz29 April 2026
4 tablet in 1 carton0781-8201-94Sandoz29 April 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 26 February 1993Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Cladribine 10 mg tablet.

Compare 1

Other strengths and forms of Cladribine

Clinical summary

Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults, among other approved uses. MedsAcross supplies Cladribine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Cladribine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Cladribine 10 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.